Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Trevogrumab-Part A · 1 trial · 1 indication
Part A
Part A
Part B
Part B
Part B
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Part A Randomized 1:1 |
| Trevogrumab | EXPERIMENTAL | Part A Randomized 1:1 |
| Arm A0 | EXPERIMENTAL | Part B Semaglutide (sema) and subcutaneous (SC) placebo and intravenous (IV) placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 |
| Arm A1 | EXPERIMENTAL | Part B Sema and SC placebo and IV placebo followed by high dose trevogrumab (trevo) Randomized 1:1:1:1:1:1:1:1 |
| Arm B0 | EXPERIMENTAL | Part B Sema, moderate-high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 |
| Arm B1 | EXPERIMENTAL | Part B Sema, moderate-high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 |
| Arm C0 | EXPERIMENTAL | Part B Sema, high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 |
| Arm C1 | EXPERIMENTAL | Part B Sema, high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 |
| Arm D0 | EXPERIMENTAL | Part B Sema, high dose trevo, and garetosmab (gareto) followed by SC placebo Randomized 1:1:1:1:1:1:1:1 |
| Arm D1 | EXPERIMENTAL | Part B Sema, high dose trevo, and gareto followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 |
| Arm 1 | EXPERIMENTAL | Part C Sema and SC placebo Randomized 1:2:2 |
| Arm 2 | EXPERIMENTAL | Part C Sema and SC low dose trevo Randomized 1:2:2 |
| Arm 3 | EXPERIMENTAL | Part C Sema and SC moderate dose trevo Randomized 1:2:2 |
| Name | Type | Description |
|---|---|---|
| Trevogrumab-Part A | DRUG | Administered IV or SC in Part A |
| Trevogrumab-Part B and Part C | DRUG | Administered SC in Part B, Part C |
| Garetosmab | DRUG | Administered IV in Part B |
| Semaglutide | DRUG | Administered SC in Part B and Part C |
| Matching Placebo-Part A | DRUG | Administered IV or SC in Part A |
| Matching Placebo-Trevogrumab | DRUG | Administered SC in Part B and Part C |
| Matching Placebo-Garetosmab | DRUG | Administered IV in Part B |
Key Inclusion Criteria Part A 1. Male or female participants age ≥18 to ≤55 years of age at the time of screening 2. BMI ≥18 and ≤32 kg/m2, at the screening visit Part B and Part C 3. Male or female participants ≥18 to ≤80 years of age at the time of screening 4. BMI ≥30 kg/m2, at the screenin...
Top 20 of 32 competitors
Trevogrumab-Part A is an investigational small molecule being studied for the treatment of obesity. It is being evaluated in a Phase 2 clinical trial for its effects on weight loss, fat loss, and lean mass preservation in adult patients with obesity.
Trevogrumab-Part A is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol REGN. The company is conducting a Phase 2 clinical trial to evaluate the drug's safety and efficacy in patients with obesity.
Trevogrumab-Part A is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 trial is active but not recruiting participants.
Trevogrumab-Part A is being studied in a Phase 2 clinical trial with the identifier NCT06299098. This randomized, double-blind, placebo-controlled trial enrolls approximately 1005 participants and is being conducted in the United States and Puerto Rico.
In the Phase 2 trial NCT06299098, Trevogrumab-Part A is being tested alone or in combination with garetosmab, both administered with semaglutide, in adult patients with obesity. The study aims to assess safety and efficacy for weight loss, fat loss, and lean mass preservation.